Astrazeneca (AZN) Non-Current Assets (2016 - 2026)

Astrazeneca has reported Non-Current Assets over the past 17 years, most recently at $84.4 billion for Q1 2026.

For Q1 2026, Non-Current Assets rose 5.35% year-over-year to $84.4 billion; the TTM value through Mar 2026 reached $84.4 billion, up 5.35%, while the annual FY2025 figure was $85.4 billion, 21.47% up from the prior year.
Non-Current Assets for Q1 2026 was $84.4 billion at Astrazeneca, down from $85.4 billion in the prior quarter.
Over five years, Non-Current Assets peaked at $85.4 billion in Q4 2025 and troughed at $68.9 billion in Q4 2022.
A 5-year average of $77.1 billion and a median of $76.7 billion in 2024 define the central range for Non-Current Assets.
On a YoY basis, Non-Current Assets climbed as much as 112.7% in 2022 and fell as far as 8.16% in 2022.
Year by year, Non-Current Assets stood at $68.9 billion in 2022, then grew by 0.15% to $69.0 billion in 2023, then rose by 1.88% to $70.3 billion in 2024, then rose by 21.47% to $85.4 billion in 2025, then dropped by 1.11% to $84.4 billion in 2026.
Business Quant data shows Non-Current Assets for AZN at $84.4 billion in Q1 2026, $85.4 billion in Q4 2025, and $84.5 billion in Q3 2025.

Peer Comparison